Loading clinical trials...
Loading clinical trials...
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Conditions
Interventions
Carboplatin
Cyclophosphamide
+3 more
Locations
1296
United States
Southern Cancer Center PC-Mobile
Mobile, Alabama, United States
Southern Cancer Center PC-Providence
Mobile, Alabama, United States
Southern Cancer Center PC-Springhill
Mobile, Alabama, United States
Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States
Anchorage Radiation Therapy Center
Anchorage, Alaska, United States
Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States
Start Date
July 26, 2015
Primary Completion Date
October 31, 2026
Completion Date
October 31, 2026
Last Updated
June 3, 2024
NCT03723928
NCT06401889
NCT07069790
NCT07122713
NCT06538389
NCT06671262
Lead Sponsor
NRG Oncology
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions